Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Tusamitamab Ravtansine (SAR408701) in Combination With Pembrolizumab and Platinum-based Chemotherapy With or Without Pemetrexed in Patients With NSQ NSCLC

Exclusion Criteria

• •Medical condition requiring concomitant administration of a medication with a strong CYP3A inhibitor.
• •Uncontrolled brain metastases and history of leptomeningeal disease.
• •Significant concomitant illness, including any severe medical condition that, in the opinion of the investigator or Sponsor, would impair the patient's participation in the study or interpretation of the results.
• •History within the last 3 years of an invasive malignancy other than the one treated in this study, with the exception of resected/ablated basal or squamous-cell carcinoma of the skin or carcinoma in situ of the cervix, or other local tumors considered cured by local treatment.
• •History of known acquired immunodeficiency syndrome (AIDS) related illnesses or known HIV disease requiring antiretroviral treatment, or active hepatitis A, B, or C infection.
• •History of active autoimmune disease that has required systemic treatment in the past 2 years.
• •History of allogeneic tissue/solid organ transplantation.
• •Active infection requiring IV systemic therapy within 2 weeks prior to randomization or active tuberculosis.
• •Interstitial lung disease or history of pneumonitis that has required oral or IV steroids
• •Non-resolution of any prior treatment-related toxicity to \< Grade 2 according to NCI CTCAE V5.0, with the exception of alopecia, vitiligo, or active thyroiditis controlled with hormone replacement therapy.
• •Unresolved corneal disorder or any previous corneal disorder considered by an ophthalmologist to predict higher risk of drug-induced keratopathy. The use of contact lenses is not permitted.
• •Symptomatic herpes zoster within 3 months prior to screening.
• •Significant allergies to humanized monoclonal antibodies.
• •Clinically significant multiple or severe drug allergies, intolerance to topical corticosteroids, or severe post-treatment hypersensitivity reactions (including, but not limited to, erythema multiforme major, linear immunoglobulin A \[IgA\] dermatosis, toxic epidermal necrolysis, and exfoliative dermatitis).
• •Concurrent treatment with any other anticancer therapy.
• •Have received prior chemotherapy treatment for advanced/metastatic NSCLC.
• •The patient is a candidate for a curative treatment with either surgical resection and/or chemoradiation
• •Washout period before the first administration of study intervention of less than 3 weeks or less than 5 times the half-life, whichever is shorter, for any investigational treatment).
• •Any prior therapy targeting CEACAM5.
• •Any prior treatment with any other anti-PD-1, or PD-L1 or programmed death ligand 2 (PD-L2), anti-CD137, or anti-cytotoxic T-lymphocyte-associated antigen-4.
• •Any prior maytansinoid treatment (DM1 or DM4 ADC).
• •Is receiving systemic steroid therapy ≤3 days prior to the first dose of study therapy or receiving any other form of immunosuppressive medication. Daily steroid replacement therapy or any corticosteroid premedication if applicable are allowed.
• •Any radiation therapy to lung \>30 Gy within 6 months of first study intervention administration.
• •Has received or will receive a live vaccine within 30 days prior to the first study intervention administration.
• •Any major surgery within the preceding 3 weeks of the first study intervention administration.
• •Prior/concurrent clinical study experience
• •Current participation in any other clinical study involving an investigational study treatment or any other type of medical research.
• •Poor organ function
• •The above information is not intended to contain all considerations relevant to a patient's potential participation in a clinical trial.